Zobrazeno 1 - 9
of 9
pro vyhledávání: '"329"'
Autor:
A Rios, JM Rodriguez-Fernandez, Rocío Parody, M Morey, Ayats R, Rozman C, Emili Montserrat, T Vallespi, Prados D, F Gomis
Publikováno v:
Blood. 64(3)
In previous studies, the prognostic value of bone marrow (BM) histologic patterns in chronic lymphocytic leukemia (CLL) has been demonstrated. In order to investigate whether such a value is independent of other prognostic parameters, a multivariate
Autor:
Yasushi Miyazaki, Yoshihiro Hatta, Toru Sakura, Noriyoshi Iriyama, Hiroshi Handa, Masatomo Takahashi, Hisashi Sakamaki, Tomohiko Taki, Norio Asou, Shunichiro Yamaguchi, Tomoya Maeda, Shinya Satou, Shuichi Miyawaki, Sumihisa Honda, Shigeki Ohtake, Tomoki Naoe, Masafumi Taniwaki
Publikováno v:
Blood. 122:2608-2608
Background Immunophenotyping is a standard diagnostic procedure in leukemia, but unlike cytogenetic classifications, which are reliable indicators for prognostic interpretation, immunophenotyping has, thus far, yielded inconsistent results. Recently,
Autor:
Yanmin Zhao, Lizhen Liu, Yi Chen, Ying Lu, Jian Yu, Kang Yu, He Huang, Xiaoyu Lai, Jimin Shi, Huarui Fu, Fei Gao, Baodong Ye, Lieguang Chen, Jianping Lan, Xiaolu Song, Yi Luo
Publikováno v:
Blood. 138:1825-1825
Objective Hematopoietic stem cell transplantation (HSCT) is one of the most efficient treatments for hematologic malignancies. However, relapse remains the main cause of transplant failure. In myeloid neoplasia, the long-term survival for patients wh
Autor:
Georg Mann, Dieter Printz, Gertraud Fröschl, Ulrike Pötschger, Gerhard Fritsch, Michael Dworzak, Helmut Gadner, Nora Mühlegger
Publikováno v:
Blood. 99(6)
Detection of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) predicts outcome. Previous studies were invariably based on relative quantification and did not investigate sample-inherent parameters that influence test accuracy, whi
Autor:
Torsten Haferlach, Susanne Schnittger, Wolfgang Kern, Tamara Alpermann, Claudia Haferlach, Sabine Jeromin
Publikováno v:
Blood. 122:2776-2776
Background SF3B1 mutations (SF3B1mut) correlate with the presence of ring sideroblasts (RS) and can be found in MDS and in AML. Aim To evaluate the incidence of SF3B1mut in a large cohort of MDS and AML patients (pts) with ≥15% RS, and furthermore
Autor:
Neeraj Agarwal, Jason Li, Nicole Hagner, Margaret M. Woo, Martijn P. Lolkema, Sunil Sharma, Emile E. Voest, Petronella O. Witteveen, Maria Grazia Porro, Dagmar Hess, Derek Mires, Sue-zette Valera
Publikováno v:
Blood. 118:5001-5001
Abstract 5001 Panobinostat is a potent class I/II/IV oral pan-deacetylase inhibitor which has shown promising clinical activity in patients with multiple myeloma and myelofibrosis, some with compromised renal and hepatic functions. The metabolism med
Autor:
Kai Neben, Bernard Klein, Uta Bertsch, Dirk Hose, Jérôme Moreaux, Hartmut Goldschmidt, Anna Jauch, Christoph Schultes, Tobias Meiβner, Joe Lewis, Christof von Kalle, Jens Hillengass, Jürgen Zimmermann, Jean François Rossi, Vladimir Benes, Thomas Möhler, Anja Seckinger, Blanka Rebacz
Publikováno v:
Blood. 114:2856-2856
Abstract 2856 Poster Board II-832 BACKGROUND. Molecular profiling of multiple myeloma allows the identification of novel targets, including HIF1A, and evaluation of their expression within large cohorts of patients. We report here the expression of H
Autor:
Chatchada Karanes, Tang-Her Jaing, Stephen J. Forman, M. Graham, Ah Moy Tan, Patrick Tan, Brian Wang, Gretchen Eames, Auayporn Nademanee, Joseph Rosenthal, Hai Peng Lin, Lawrence Petz, David W. Gjertson, Tiffany Chow, Lee Lee Chan, Robert Chow, Tina Wu
Publikováno v:
Blood. 112:4406-4406
Unrelated cord blood (UCB) is an important stem cell source for unrelated hematopoietic cell transplantation of patients with non-malignant disorders. Cell dosage is a critical factor for successful UCB hematopoietic stem cell transplantation (HSCT).
Autor:
Lisa Rybicki, Brian J. Bolwell, Ronald Sobecks, Elizabeth Kuczkowski, Stacey Brown, Steven Andresen, Matt Kalaycio, Brad Pohlman
Publikováno v:
Blood. 106:1764-1764
Many high-dose chemotherapy preparative regimens include agents known to cause pulmonary toxicity such as BCNU. Chemotherapy induced pulmonary toxicity may be fatal. From 1/1/93 to 12/31/04 we treated 533 NHL patients with oral busulfan 14mg/kg, VP-1